每周一次胰岛素Icodec不同滴定策略与每日一次甘精胰岛素U100的随机开放标签比较
本研究为2期随机开放标签16周达标治疗研究,纳入205例口服药控制不佳的2型糖尿病成人,比较每周一次Icodec三种滴定方案与每日一次甘精胰岛素U100的疗效与安全性。结果显示滴定方案B的TIR优于甘精胰岛素U100,差异7.08个百分点(95%CI 2.12至12.04;P=0.005)。所有组低血糖发生率低且无严重低血糖,方案A在血糖控制与低血糖风险间平衡最佳。
要点
- 每周一次Icodec三种滴定方案均有效且耐受性良好。
- 滴定方案B的TIR较甘精胰岛素U100显著提高7.08个百分点。
- 方案A(目标80-130 mg/dL,±21单位/周)血糖控制与低血糖风险平衡最佳。
核心结论
- 每周一次Icodec在三种滴定方案下均有效且耐受性良好。
- 滴定方案A在血糖控制与低血糖风险之间显示最佳平衡。
研究设计与样本
- 2期随机开放标签16周达标治疗研究。
- 纳入205例口服降糖药治疗中HbA1c 7-10%的胰岛素初治2型糖尿病成人。
- 随机分为Icodec滴定A组(n=51)、B组(n=51)、C组(n=52)或甘精胰岛素U100组(n=51),均每周滴定。
主要发现
- TIR从基线(均值:A 57.0%;B 55.2%;C 51.0%;IGlar U100 55.3%)改善至第15-16周(估计均值:A 76.6%;B 83.0%;C 80.9%;IGlar U100 75.9%)。
- 滴定方案B的TIR优于IGlar U100(估计治疗差异7.08个百分点;95%CI 2.12至12.04;P=0.005)。
- 2级低血糖(<54 mg/dL)发生率低(A、B、C和IGlar U100组分别为每患者暴露年0.05、0.15、0.38、0.00事件),无严重低血糖。
关键数值与推荐
- Icodec滴定A:餐前自测血糖目标80-130 mg/dL,每周调整±21单位。
- Icodec滴定B:目标80-130 mg/dL,每周调整±28单位。
- Icodec滴定C:目标70-108 mg/dL,每周调整±28单位。
- 甘精胰岛素U100:目标80-130 mg/dL,每日调整±4单位。
临床怎么用
- 每周一次Icodec可作为基础胰岛素选择,滴定方案A可能兼顾疗效与安全性。
- 临床需根据血糖目标选择滴定算法,方案B降糖更强但需关注低血糖。
局限性
- 为2期研究,样本量较小(n=205),随访仅16周。
- 开放标签设计可能引入偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Insulin icodec is a novel once-weekly basal insulin analog. This trial investigated the efficacy and safety of icodec using different once-weekly titration algorithms. RESEARCH DESIGN AND METHODS: This was a phase 2, randomized, open-label, 16-week, treat-to-target study. Insulin-naive adults (n = 205) with type 2 diabetes and HbA1c 7-10% while treated with oral glucose-lowering medications initiated once-weekly icodec titrations A (prebreakfast self-measured blood glucose target 80-130 mg/dL; adjustment ±21 units/week; n = 51), B (80-130 mg/dL; ±28 units/week; n = 51), or C (70-108 mg/dL; ±28 units/week; n = 52), or once-daily insulin glargine 100 units/mL (IGlar U100) (80-130 mg/dL; ±4 units/day; n = 51), all titrated weekly. Percentage of time in range (TIR) (70-180 mg/dL) during weeks 15 and 16 was measured using continuous glucose monitoring. RESULTS: TIR improved from baseline (means: A, 57.0%; B, 55.2%; C, 51.0%; IGlar U100, 55.3%) to weeks 15 and 16 (estimated mean: A, 76.6%; B, 83.0%; C, 80.9%; IGlar U100, 75.9%). TIR was greater for titration B than for IGlar U100 (estimated treatment difference 7.08%-points; 95% CI 2.12 to 12.04; P = 0.005). No unexpected safety signals were observed. Level 2 hypoglycemia (<54 mg/dL) was low in all groups (0.05, 0.15, 0.38, 0.00 events per patient-year of exposure for icodec titrations A, B, and C and IGlar U100, respectively), with no episodes of severe hypoglycemia. CONCLUSIONS: Once-weekly icodec was efficacious and well tolerated across all three titration algorithms investigated. The results for icodec titration A (80-130 mg/dL; ±21 units/week) displayed the best balance between glycemic control and risk of hypoglycemia.
引用
- Lingvay I, Buse JB, Franek E, et al. A Randomized, Open-Label Comparison of Once-Weekly Insulin Icodec Titration Strategies Versus Once-Daily Insulin Glargine U100. Diabetes Care. 2021. PMID: 33875484. doi:10.2337/dc20-2878
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。